CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer

Cardio-Oncology

Table 4 Most frequently prescribed medications associated with QTc prolongation in patients without CV comorbidities

Medications with risk of QTc prolongation used for > 30 days	Patients without CV comorbidities (n = 2496)
The 5 most frequently prescribed medications with risk of QTc prolongation, n (%)
Venlafaxine	250 (10.0)
Escitalopram	178 (7.1)
Hydrocodone	146 (5.8)
Injection, diphenhydramine HCl, up to 50 mg	137 (5.5)
Pantoprazole	116 (4.6)
The 5 most frequently prescribed medications with known risk of TdP^a, n (%)
Escitalopram	178 (7.1)
Citalopram	98 (3.9)
Ondansetron	74 (3.0)
Injection, ondansetron HCl, per 1 mg	43 (1.7)
Hydroxychloroquine	38 (1.5)
The 5 most frequently prescribed medications with possible risk of TdP^b, n (%)
Venlafaxine	250 (10.0)
Hydrocodone	146 (5.8)
Injection, granisetron HCl, 100 mcg	89 (3.6)
Injection, palonosetron HCl, 25 mcg	89 (3.6)
Levetiracetam	40 (1.6)
The 5 most frequently prescribed medications with conditional risk of TdP^c, n (%)
Injection, diphenhydramine HCl, up to 50 mg	137 (5.5)
Pantoprazole	116 (4.6)
Sertraline	113 (4.5)
Omeprazole	90 (3.6)
Trazodone	46 (1.8)

CV Cardiovascular, QTc Heart rate-corrected QT interval, TdP Torsades de Pointes
^aDrugs that prolong QTc and are clearly associated with a known risk of TdP, even when taken as recommended
^bDrugs that can cause QTc prolongation, but currently lack evidence for a risk of TdP when taken as recommended
^cDrugs that are associated with TdP, but only under certain conditions of their use or by creating conditions that facilitate or induce TdP

ISSN: 2057-3804